A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Denmark’s Rasmus Hojgaard produced a brilliant finish to win the Amgen Irish Open as Rory McIlroy suffered a second ...

Shane Lowry set his sights on a Sunday showdown with Rory McIlroy after the headline attractions played their way into ...

The Dow Jones Industrial Average needs to rise nearly 20% to hit a new milestone. That doesn’t seem likely next year. But ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

“I’m right in the mix,” claimed McIlroy, the world number three, after posting a second round 68 – five birdies and one lone ...

Bob MacIntyre reckoned it was a case of “robbery” as he shot the “best two-under-par round of my life” to be in the mix along ...

Tarsus Pharmaceuticals is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 ...

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

The surge in global cancer cases is raising serious concerns among experts. A recent study published in Monday in Cancer, a ...